NCT06188793 Virtual Reality (VR) -Directed Brain Gut Behavioral Treatment (BGBT) for Inflammatory Bowel Disease (IBD) Inpatients
| NCT ID | NCT06188793 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Michigan |
| Condition | Inflammatory Bowel Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-02-13 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2024-02-13 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The research is studying virtual reality (VR)-directed brain-gut behavioral therapy (BGBT) as a pain treatment option for hospitalized patients with inflammatory bowel disease (IBD). This study is being done to learn if VR-directed BGBT is feasible and acceptable for patients with IBD in addressing pain in the hospital setting. The study hypothesizes that: * At least 75% of enrolled participants will complete the VR-directed BGBT inpatient program * Hospitalized patients with IBD will find VR-directed BGBT acceptable as a pain treatment option in the inpatient setting.
Eligibility Criteria
Inclusion Criteria: * Patients with Inflammatory Bowel Disease and self-reported pain * Hospitalized for management of IBD (inpatient medicine services at Michigan Medicine) Exclusion Criteria: * Patients that do not report pain * Anticipated length of hospital stay is less than 72 hours * Patients that have previously had a seizure, loss of awareness, or other symptoms linked to an epileptic condition * Patients with binocular vision loss * Patients with an uncontrolled cardiac condition such as an arrhythmia, coronary artery disease, or neurological/cerebrovascular disease. * Patients that are currently pregnant
Contact & Investigator
Shirley Cohen-Mekelburg, MD, MS
PRINCIPAL INVESTIGATOR
University of Michigan
Frequently Asked Questions
Who can join the NCT06188793 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Inflammatory Bowel Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06188793 currently recruiting?
Yes, NCT06188793 is actively recruiting participants. Contact the research team at shcohen@med.umich.edu for enrollment information.
Where is the NCT06188793 trial being conducted?
This trial is being conducted at Ann Arbor, United States.
Who is sponsoring the NCT06188793 clinical trial?
NCT06188793 is sponsored by University of Michigan. The principal investigator is Shirley Cohen-Mekelburg, MD, MS at University of Michigan. The trial plans to enroll 40 participants.